Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinoma

Phase 1

• Conditions: non-medullary thyroid carcinoma

• Registration Number: EUCTR2007-002365-13-NL
• Lead Sponsor: Bayer B.V.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-05-11
• Study Completion: 2008-12-10
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

·Patients with non-medullary thyroid carcinoma
·The patients must have undergone total thyroidectomy
·Presence of metastases or inoperable recurrent disease, as proven by elevated serum thyroglobulin levels (Tg) in combination with radiological evidence for tumor.
·No or insufficient RaI uptake in tumor as proven by RaI scintigraphy, performed after prior RaI therapy.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

·Pregnancy
·Other active malignancies
·Active kidney, liver or pancreatic disease or dysfunction
·Unstable angina pectoris or recent (<3 months) myocardial infarction.
·Coagulopathy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified